Abraham Ceesay is Chief Executive Officer of Rapport Therapeutics. Prior to joining Rapport, he served as President of Cerevel Therapeutics from May 2021 through February 2023. Earlier, he was Chief Executive Officer of Tiburio Therapeutics, where he built a fully integrated organization and advanced a program to investigational new drug (IND) enablement for a rare neuroendocrine tumor. Prior to Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme.
Mr. Ceesay serves on the boards of Rapport Therapeutics, Pacira Biosciences, and Life Science Cares, as well as on the Board of Trustees of Thayer Academy. He has been a director of Charles River since May 2025. His qualifications to serve as a director include his nearly two decades of executive and public company biopharmaceutical industry experience.